Current radiopharmaceuticals最新文献

筛选
英文 中文
Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98). 极低频电磁场、辐射和替莫唑胺在球状和单层胶质母细胞瘤细胞系中的比较研究(T98)。
IF 2.3 4区 医学
Current radiopharmaceuticals Pub Date : 2023-01-01 DOI: 10.2174/1874471016666221207163043
Rasoul Yahyapour, Samideh Khoei, Zeinab Kordestani, Mohammad Hasan Larizadeh, Ali Jomehzadeh, Maryam Amirinejad, Meysam Ahmadi-Zeidabadi
{"title":"Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).","authors":"Rasoul Yahyapour,&nbsp;Samideh Khoei,&nbsp;Zeinab Kordestani,&nbsp;Mohammad Hasan Larizadeh,&nbsp;Ali Jomehzadeh,&nbsp;Maryam Amirinejad,&nbsp;Meysam Ahmadi-Zeidabadi","doi":"10.2174/1874471016666221207163043","DOIUrl":"https://doi.org/10.2174/1874471016666221207163043","url":null,"abstract":"<p><strong>Background: </strong>Glioblastoma is the most common primary malignant tumor of the central nervous system. The patient's median survival rate is 13.5 months, so it is necessary to explore new therapeutic approaches.</p><p><strong>Objective: </strong>Extremely low-frequency electromagnetic field (EMF) has been explored as a noninvasive cancer treatment. This study applied the EMF with previous conventional chemoradiotherapy for glioblastoma.</p><p><strong>Methods: </strong>In this study, we evaluated the cytotoxic effects of EMF (50 Hz, 100 G), temozolomide (TMZ), and radiation (Rad) on gene expression of T98 glioma cell lines in monolayer and spheroid cell cultures.</p><p><strong>Results: </strong>Treatment with Rad and EMF significantly increased apoptosis-related gene expression compared to the control group in monolayers and spheroids (p<0.001). The expression of apoptotic-related genes in monolayers was higher than the similar spheroid groups (p<0.001). We found that treatment with TMZ and EMF could increase the gene expression of the autophagy cascade markers compared to the control group (p<0.001). Autophagy-related gene expression in spheroids was higher than in the similar monolayer group (p<0.001). We demonstrated that coadministration of EMF, TMZ, and Rad significantly reduced cell cycle and drug resistance gene expression in monolayers and spheroids (p<0.001) compared to the control group.</p><p><strong>Conclusion: </strong>The combinational use of TMZ, Rad and, EMF showed the highest antitumor activity by inducing apoptosis and autophagy signaling pathways and inhibiting cell cycle and drug resistance gene expression. Furthermore, EMF increased TMZ or radiation efficiency.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 2","pages":"123-132"},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9920713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A New Buffer for Gallium-68 Labeling Suitable for use in Nuclear Medicine; Triethanolamine (TEA). 一种适用于核医学的镓-68标记缓冲液三乙醇胺(茶)。
IF 2.3 4区 医学
Current radiopharmaceuticals Pub Date : 2023-01-01 DOI: 10.2174/1874471016666230522100024
Ayşe Uğur, Olga Yaylali, Doğangün Yüksel
{"title":"A New Buffer for Gallium-68 Labeling Suitable for use in Nuclear Medicine; Triethanolamine (TEA).","authors":"Ayşe Uğur,&nbsp;Olga Yaylali,&nbsp;Doğangün Yüksel","doi":"10.2174/1874471016666230522100024","DOIUrl":"https://doi.org/10.2174/1874471016666230522100024","url":null,"abstract":"<p><strong>Background: </strong>Radiopharmaceuticals labeled with [<sup>68</sup>Ga] from positron emission tomography (PET) radionuclides are utilized in nuclear medicine for non-invasive in vivo molecular imaging. Buffer solutions for radiolabeling play an important role as choosing the right buffer for the reaction helps to obtain high yield radiopharmaceuticals. Zwitterionic organic buffer 4-(2- hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), sodium acetate (CH<sub>3</sub>COONa), sodium bicarbonate (NaHCO<sub>3</sub>) buffers are widely used for labeling of peptides with [<sup>68</sup>Ga]Cl<sub>3</sub>. They can be used for peptide labelings with the acidic [<sup>68</sup>Ga]Cl<sub>3</sub> precursor of triethanolammonium (TEA) buffer. The cost and toxicity of TAE buffer are relatively low.</p><p><strong>Method: </strong>For [<sup>68</sup>Ga]GaPSMA-HBED-CC and [<sup>68</sup>Ga]GaDOTA-TATE labeling, the effectiveness of TEA buffer without chemical impurities in radiolabeling reactions and QC parameters in successful labeling was investigated.</p><p><strong>Results: </strong>The method used to label [<sup>68</sup>Ga]Cl<sub>3</sub> with PSMA-HBED-CC peptide in the presence of TEA buffer was successful when applied at room temperature. High purity radiosynthesis suitable for clinical use was performed to obtain DOTA-TATE peptide with the addition of 363K temperature and radical scavenger. Quality control tests with R-HPLC have shown that this method is suitable for clinical use.</p><p><strong>Conclusion: </strong>We present an alternative procedure for labeling PSMA-HBED-CC and DOTATATE peptides with [<sup>68</sup>GaCl<sub>3</sub>] to obtain high radioactive doses of final radiopharmaceutical products used in nuclear medicine clinical applications. We have provided a quality-controlled final product that can be used in clinical diagnostic procedures. With the use of an alternative buffer, these methods could be adapted to semi-automatic or automated modules routinely used in nuclear medicine laboratories to label [<sup>68</sup>Ga]-based radiopharmaceuticals.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 4","pages":"308-314"},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10139588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Status of α-emitter Radioimmunoconjugates for Targeted Therapy. 靶向治疗α-发射器放射免疫偶联物的现状
IF 2.3 4区 医学
Current radiopharmaceuticals Pub Date : 2023-01-01 DOI: 10.2174/1874471016666230106111119
Mobina Rabiei, Ahmad Reza Vaez Alaei, Hassan Yousefnia
{"title":"Status of α-emitter Radioimmunoconjugates for Targeted Therapy.","authors":"Mobina Rabiei,&nbsp;Ahmad Reza Vaez Alaei,&nbsp;Hassan Yousefnia","doi":"10.2174/1874471016666230106111119","DOIUrl":"https://doi.org/10.2174/1874471016666230106111119","url":null,"abstract":"<p><p>This minireview describes the global situation of ongoing research and development and the clinical application of alpha emitter labeled immunoconjugates with various alpha emitters with an overview of the future trends. The potentially helpful alpha emitter radioisotopes for medical applications, chelators, and immunomolecules of interest for future alpha radioimmunotherapy are discussed. Challenges and some suggested future works on chelators are also presented.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 2","pages":"85-94"},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9929625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthesis and Ready to Use Kit Formulation of EDTMP for the Preparation of 177Lu-EDTMP as a Bone Palliation Radiopharmaceutical. 骨缓解放射性药物177Lu-EDTMP的合成及即用型试剂盒配制
IF 2.3 4区 医学
Current radiopharmaceuticals Pub Date : 2023-01-01 DOI: 10.2174/1874471015666220721095938
Guldem Mercanoglu, Kani Zilbeyaz, Nuri Arslan
{"title":"Synthesis and Ready to Use Kit Formulation of EDTMP for the Preparation of 177Lu-EDTMP as a Bone Palliation Radiopharmaceutical.","authors":"Guldem Mercanoglu,&nbsp;Kani Zilbeyaz,&nbsp;Nuri Arslan","doi":"10.2174/1874471015666220721095938","DOIUrl":"https://doi.org/10.2174/1874471015666220721095938","url":null,"abstract":"<p><strong>Introduction: </strong>With its suitable nuclear decay characteristics and large-scale production feasibility with adequate specific activity, <sup>177</sup>Lu is regarded as an excellent radionuclide for developing bone pain palliation agent. Ethylenediamine-tetramethylene phosphonic acid (EDTMP) is a preferred carrier molecule for radiolanthanides, such as <sup>177</sup>Lu. The present paper describes the synthesis of EDTMP and the development of a ready-to-use kit for the preparation of <sup>177</sup>Lu-EDTMP and its quality control in accordance with the quality and safety criteria required for medicinal use.</p><p><strong>Material and methods: </strong>EDTMP was synthesized by a modified Mannich-type reaction, and the structure was characterized using NMR and IR spectroscopy. Optimization of radiolabeling conditions was done with two different salt forms of EDTMP. The labeling yield was checked by paper chromatography with radiation detection. Kit was developed as a lyophilized mixture of EDTMP and sodium bicarbonate in a maximum volume of 5 mL. Labeling efficiency, radionuclidic purity, radiochemical purity, sterility, and pyrogenicity analysis were performed as the quality control of the labeled kit.</p><p><strong>Results: </strong>The analytical data for the structure determination and purity of the synthesized ligand were in agreement with authentic commercial samples used in radiopharmacy.<sup>177</sup>Lu-EDTMP complex was prepared using synthesized EDTMP ligand under optimized labeling conditions with high labelling yield (>99%). The radiolabeling yields of the EDTMP kit at room temperature after 30 min and 48 hours were 99.46% and 99.00%.</p><p><strong>Conclusion: </strong>The developed EDTMP kit enables an instant one-step preparation of the radiopharmaceutical of high radiochemical purity (>99%) and has a sufficiently long shelf life. This enables the routine production of the <sup>177</sup>Lu-EDTMP in nuclear medicine clinics without requiring experienced staff.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 1","pages":"38-43"},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9474341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Bone Scan Index as a Prognostic Tool in Breast Cancer Patients with Bone Metastasis. 骨扫描指数作为乳腺癌骨转移患者预后工具的评价。
IF 2.3 4区 医学
Current radiopharmaceuticals Pub Date : 2023-01-01 DOI: 10.2174/1874471016666230509113108
Maria Silvia De Feo, Viviana Frantellizzi, Arianna Di Rocco, Alessio Farcomeni, Antonio Matto, Andrea Marongiu, Susanna Nuvoli, Angela Spanu, Giuseppe De Vincentis
{"title":"Evaluation of Bone Scan Index as a Prognostic Tool in Breast Cancer Patients with Bone Metastasis.","authors":"Maria Silvia De Feo,&nbsp;Viviana Frantellizzi,&nbsp;Arianna Di Rocco,&nbsp;Alessio Farcomeni,&nbsp;Antonio Matto,&nbsp;Andrea Marongiu,&nbsp;Susanna Nuvoli,&nbsp;Angela Spanu,&nbsp;Giuseppe De Vincentis","doi":"10.2174/1874471016666230509113108","DOIUrl":"https://doi.org/10.2174/1874471016666230509113108","url":null,"abstract":"<p><strong>Background: </strong>Bone metastatic involvement represents a leading cause of death in patients with advanced breast cancer (BC). At present, it is not clear whether the bone metastatic load might impact Overall Survival (OS) in patients with bone metastatic BC at diagnosis. For this purpose, we used the Bone Scan Index (BSI), which is a reproducible and quantitative expression of tumor load observed at bone scintigraphy.</p><p><strong>Objective: </strong>The aim of this study was to associate BSI with OS in bone metastatic BC patients.</p><p><strong>Methods: </strong>In this retrospective study, we enrolled BC patients with bone metastases at the scintigraphic bone scan performed for staging purposes. The BSI was calculated through the DASciS software, and statistical analysis was carried out. Other clinical variables relevant to OS analysis were taken into account.</p><p><strong>Results: </strong>Of a total of 94 patients, 32% died. In most cases, the histotype was ductal infiltrating carcinoma. The median OS from diagnosis was 72 months (CI 95%: 62-NA). The univariate analysis with COX regression showed that only hormone therapy significantly correlates with OS (HR 0.417, CI 95%: 0.174-0.997, p < 0.049). As concerning BSI, the statistical analysis showed that it does not predict OS in BC patients (HR 0.960, 95% CI: 0.416-2.216, p < 0.924).</p><p><strong>Conclusion: </strong>Although the BSI significantly predicts OS in prostate cancer and in other tumors, we observed that the metastatic load of bone disease has not a key role in prognostic stratification in our population.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 4","pages":"284-291"},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10132987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Novel Tumor Hypoxia Imaging Agent: [99mTc]Tc(CO)3-CPA-2-NIM. 新型肿瘤缺氧显像剂:[99mTc]Tc(CO)3-CPA-2-NIM。
IF 2.3 4区 医学
Current radiopharmaceuticals Pub Date : 2023-01-01 DOI: 10.2174/1874471016666230320144641
Xiao Lin, Xiaojie Tan, Fengyu Wu, Qian Yu
{"title":"A Novel Tumor Hypoxia Imaging Agent: [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-CPA-2-NIM.","authors":"Xiao Lin,&nbsp;Xiaojie Tan,&nbsp;Fengyu Wu,&nbsp;Qian Yu","doi":"10.2174/1874471016666230320144641","DOIUrl":"https://doi.org/10.2174/1874471016666230320144641","url":null,"abstract":"<p><strong>Introduction: </strong>Hypoxia imaging agents can selectively remain in hypoxic tissue, which can directly reflect the location and degree of hypoxia.</p><p><strong>Methods: </strong>Synthesized a novel tumor hypoxia imaging probe [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-CPA-2-NIM and evaluated its biological behavior with the purpose to assess its possibility of becoming a qualified tumor hypoxia imaging agent.</p><p><strong>Results: </strong>Radiochemcial purity of [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-CPA-2-NIM was greater than 95% after HPLC purification. Lipophilicity coefficient of this complex was -1.74 ± 0.10 (n = 5, number of experiments), indicating it was a hydrophilic complex. <i>In vitro</i> cell experiments demonstrated that this complex has selectivity for hypoxia at oxygen concentrations < 10 ppm (parts per million). Biodistribution experiment in S180 tumor bearing mice showed that tumor uptake reached its highest at 2 h post-injection with mice tumor-to-muscle ratio.</p><p><strong>Conclusions: </strong>Complex [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-CPA-2-NIM has the possibility of becoming a tumor hypoxia imaging agent.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 4","pages":"300-307"},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10144638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dose-response Analysis in Hepatic Tumors Treated with 90Y-TARE According to a Personalized Dosimetric Workflow: Preliminary Results. 根据个性化剂量测定工作流程对90Y-TARE治疗肝肿瘤的剂量反应分析:初步结果。
IF 2.3 4区 医学
Current radiopharmaceuticals Pub Date : 2023-01-01 DOI: 10.2174/1874471016666230608100921
Alessia Milano, Amedeo Capotosti, Luca Zagaria, Germano Perotti, Alessio Rizzo, Valentina Longo, Davide De Leoni, Roberto Moretti, Laura Breschi, Guenda Meffe, Lorenzo Placidi, Davide Cusumano, Lucia Cerrito, Salvatore Annunziata, Roberto Iezzi, Luca Indovina
{"title":"Dose-response Analysis in Hepatic Tumors Treated with 90Y-TARE According to a Personalized Dosimetric Workflow: Preliminary Results.","authors":"Alessia Milano,&nbsp;Amedeo Capotosti,&nbsp;Luca Zagaria,&nbsp;Germano Perotti,&nbsp;Alessio Rizzo,&nbsp;Valentina Longo,&nbsp;Davide De Leoni,&nbsp;Roberto Moretti,&nbsp;Laura Breschi,&nbsp;Guenda Meffe,&nbsp;Lorenzo Placidi,&nbsp;Davide Cusumano,&nbsp;Lucia Cerrito,&nbsp;Salvatore Annunziata,&nbsp;Roberto Iezzi,&nbsp;Luca Indovina","doi":"10.2174/1874471016666230608100921","DOIUrl":"10.2174/1874471016666230608100921","url":null,"abstract":"<p><strong>Background: </strong>Transarterial Radioembolization (TARE) is a widespread radiation therapy for unresectable hepatic lesions, but a clear understanding of the dose-response link is still missing. The aim of this preliminary study is to investigate the role of both dosimetric and clinical parameters as classifiers or predictors of response and survival for TARE in hepatic tumors and to present possible response cut-off.</p><p><strong>Methods: </strong>20 patients treated with glass or resin microspheres according to a personalized workflow were included. Dosimetric parameters were extracted from personalized absorbed dose maps obtained from the convolution of 90Y PET images with 90Y voxel S-values.</p><p><strong>Results: </strong>D<sub>95</sub> ≥ 104 Gy and tumor mean absorbed dose MADt ≥ 229 Gy were found to be optimal cut-off values for complete response, while D<sub>30</sub> ≥ 180 Gy and MAD<sub>t</sub> ≥ 117 Gy were selected as cut-off values for at least partial response and predicted better survival. Clinical parameters Alanine Transaminase (ALT) and Model for End-Stage Liver Disease (MELD) didn't show sufficient classification capability for response or survival.</p><p><strong>Concusion: </strong>These preliminary results highlight the importance of an accurate dosimetric evaluation and suggest a cautious approach when considering clinical indicators. Dosimetric cut-off values could be a support tool in both planning and post-treatment phases. Larger multi-centric randomized trials, with standardized methods regarding patient selection, response criteria, Regions of Interest definition, dosimetric approach and activity planning are needed to confirm these promising results.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 4","pages":"326-336"},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10127654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of Radiolabeled Nanomaterials. 放射性标记纳米材料的影响。
IF 2.3 4区 医学
Current radiopharmaceuticals Pub Date : 2023-01-01 DOI: 10.2174/1874471016666230523155711
Martha Sahylí Ortega Pijeira, Natália Cristina Gomes da Silva, Luciana Magalhaes Rebelo Alencar, Eduardo Ricci-Junior, Ralph Santos-Oliveira
{"title":"The Impact of Radiolabeled Nanomaterials.","authors":"Martha Sahylí Ortega Pijeira,&nbsp;Natália Cristina Gomes da Silva,&nbsp;Luciana Magalhaes Rebelo Alencar,&nbsp;Eduardo Ricci-Junior,&nbsp;Ralph Santos-Oliveira","doi":"10.2174/1874471016666230523155711","DOIUrl":"10.2174/1874471016666230523155711","url":null,"abstract":"<p><p>Nanotechnology has changed the world, with a great impact on industry and medicine. In this commentary, we discuss the importance of radiolabeled nanomaterials for the construction of theranostic, imaging and therapeutic agents in order to pave the future of medicine.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 4","pages":"337-339"},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10479849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Evaluation of the Mitigation Effect of Spirulina Against Lung Injury Induced by Radiation in Rats. 螺旋藻对大鼠放射性肺损伤的缓解作用评价。
IF 2.3 4区 医学
Current radiopharmaceuticals Pub Date : 2023-01-01 DOI: 10.2174/1874471015666220418133919
Mohammad Hootan Ahmadvand, Safoora Nikzad, Vahid Changizi, Abdolazim Sedighi Pashaki, Masoud Najafi, Fatemeh Mirzaei
{"title":"Evaluation of the Mitigation Effect of Spirulina Against Lung Injury Induced by Radiation in Rats.","authors":"Mohammad Hootan Ahmadvand,&nbsp;Safoora Nikzad,&nbsp;Vahid Changizi,&nbsp;Abdolazim Sedighi Pashaki,&nbsp;Masoud Najafi,&nbsp;Fatemeh Mirzaei","doi":"10.2174/1874471015666220418133919","DOIUrl":"https://doi.org/10.2174/1874471015666220418133919","url":null,"abstract":"<p><strong>Background: </strong>Some compounds have been investigated to mitigate the effect of radiation on the lung, such as pneumonitis and fibrosis.</p><p><strong>Objective: </strong>This study aimed to examine the mitigation efficiency of Spirulina compared to the effect of Metformin.</p><p><strong>Methods: </strong>25 male Wistar rats were allotted in five groups: control, Spirulina, Radiation, Radiation plus Spirulina, and Radiation plus Metformin. Rat chest regions were irradiated by 15 Gray (Gy) xradiation using aLINAC. Forty-eight hours after irradiation, treatment with Spirulina and Metformin began. Eighty days after irradiation, all rats were sacrificed, and their lung tissues were removed for histopathological, and biochemical assays.</p><p><strong>Results: </strong>The results demonstrated that irradiation increased MDA (Malondialdehyde) levels while suppressing the SOD (superoxide dismutase) and GPx(glutathione peroxidase) activity in the irradiated group. MDA levels in lung tissues were reduced with Metformin but not with Spirulina. Both Metformin and Spirulina increased the SOD and GPx activity in lung tissue. Moreover, histopathological evaluations showed extensive changes in the lung tissue including infiltration of lymph cells around the bronchioles and blood vessels, thickening of the alveolar wall, and the disruption of the alveolar structure, as well as accumulation of collagen fibers. Administration of Spirulina and Metformin significantly reduced pathological changes in lung tissue, although the effect of Metformin was greater than that of Spirulina.</p><p><strong>Conclusion: </strong>Spirulina could mitigate radiation-induced lung injury moderately, although Metformin is more effective than Spirulina as a mitigator agent.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 1","pages":"71-77"},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9431074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimization of SUV with Changing the Dose Amount in F18-FDG PET/CT of Pediatric Lymphoma Patients. 改变剂量的SUV对儿童淋巴瘤患者F18-FDG PET/CT的优化
IF 2.3 4区 医学
Current radiopharmaceuticals Pub Date : 2023-01-01 DOI: 10.2174/1874471016666221118114726
Nedim Cüneyt Murat Gülaldi, Berkay Cagdas, Fatma Arzu Görtan
{"title":"Optimization of SUV with Changing the Dose Amount in F18-FDG PET/CT of Pediatric Lymphoma Patients.","authors":"Nedim Cüneyt Murat Gülaldi,&nbsp;Berkay Cagdas,&nbsp;Fatma Arzu Görtan","doi":"10.2174/1874471016666221118114726","DOIUrl":"https://doi.org/10.2174/1874471016666221118114726","url":null,"abstract":"<p><strong>Aims: </strong>We aim to reveal an effect of residual activity leftover within the medical materials other than the empty syringe used for injection of the tracer on SUV measurements and consequently effect on possible treatment response assessment.</p><p><strong>Background: </strong>Staging and follow-up of pediatric lymphoma patients mainly achieved by the help of PET/CT scans. It is crucial to make an optimal imaging technique for interpreting individual images and assessing treatment response.</p><p><strong>Objective: </strong>Standardized uptake value measurement is an important quantification parameter in PET/CT scanning of childhood lymphomas. Low dose of activity used in pediatric oncology patients makes them vulnerable to small changes of input values for subsequent metabolic parameters.</p><p><strong>Methods: </strong>Sixty-eight pediatric lymphoma patients below 50 kg were included into the study. SUVmax, SUVpeak values of the most metabolically active lesions, along with liver and mediastinum, were recorded. Metabolic parameters of the lesions/lymph nodes, mediastinum and liver parenchyma were compared before and after counts from medical materials other than empty syringe were taken into account. Wilcoxon signed-rank test was used for non-parametric paired sampled tests for the groups.</p><p><strong>Results: </strong>There were statistically significant differences between the whole 6 above-mentioned groups confirming the importance of residual counts on metabolic parameters (p < 0.001).</p><p><strong>Conclusion: </strong>Our study demonstrated residual radioactivity in medical materials such as serum line tubes, i.v. catheters, three-way stopcock and also butterfly needles used during intravenous injection should also be included for optimum quantitative metabolic parameter values and to minimize its the adverse effect on treatment response evaluation, especially in borderline lesions.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 2","pages":"151-157"},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9920224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信